These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23512270)

  • 1. Dose rounding of ipilimumab in adult metastatic melanoma patients results in significant cost savings.
    Jarkowski A; Nestico JS; Vona KL; Khushalani NI
    J Oncol Pharm Pract; 2014 Feb; 20(1):47-50. PubMed ID: 23512270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential cost savings by dose down-rounding of monoclonal antibodies in a community cancer center.
    Copur MS; Gnewuch C; Schriner M; Tharnish M; Gonen M; McDonald M; Kezeor J; Ramaekers RC; Gauchan D; Clark D; Greenwalt L; Mickey M; Norvell M
    J Oncol Pharm Pract; 2018 Mar; 24(2):116-120. PubMed ID: 29284380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the dosing strategies of biologic agents and the theoretical impact of dose rounding.
    Lindsey S; Parsons LB; Figg LR; Rhodes J
    J Oncol Pharm Pract; 2018 Jan; 24(1):47-55. PubMed ID: 29251257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost savings analysis and toxicity audit of a bevacizumab dose rounding policy at a community cancer center.
    Moore DC; McVey GN
    J Oncol Pharm Pract; 2018 Jan; 24(1):42-46. PubMed ID: 27760811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential cost savings associated with dose rounding antineoplastic monoclonal agents.
    Francis SM; Heyliger A; Miyares MA; Viera M
    J Oncol Pharm Pract; 2015 Aug; 21(4):280-4. PubMed ID: 24821690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rounding rituximab dose to nearest vial size.
    Patel S; Le A
    J Oncol Pharm Pract; 2013 Sep; 19(3):218-21. PubMed ID: 23114093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Financial Impact of an Automated Oncology Dose-Rounding Initiative: One-Year Analysis.
    Dela-Pena JC; Eschenburg KA; LaRocca VW; Patel D; Hough SM
    JCO Clin Cancer Inform; 2021 Aug; 5():805-810. PubMed ID: 34351786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the potential impact of dose rounding parenteral chemotherapy agents on cost savings and drug waste minimization.
    Chillari KA; Southward J; Harrigan N
    J Oncol Pharm Pract; 2018 Oct; 24(7):507-510. PubMed ID: 28732452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of dose rounding of chemotherapy to the nearest vial size.
    Dooley MJ; Singh S; Michael M
    Support Care Cancer; 2004 Sep; 12(9):653-6. PubMed ID: 14986078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost avoidance from dose rounding biologic and cytotoxic antineoplastics.
    Vandyke TH; Athmann PW; Ballmer CM; Kintzel PE
    J Oncol Pharm Pract; 2017 Jul; 23(5):379-383. PubMed ID: 27000279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis.
    Barzey V; Atkins MB; Garrison LP; Asukai Y; Kotapati S; Penrod JR
    J Med Econ; 2013; 16(2):202-12. PubMed ID: 23057750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost savings from dose rounding of biologic anticancer agents in adults.
    Winger BJ; Clements EA; DeYoung JL; O'Rourke TJ; Claypool DL; Vachon S; VanDyke TH; Zimmer-Young J; Kintzel PE
    J Oncol Pharm Pract; 2011 Sep; 17(3):246-51. PubMed ID: 20332175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimising treatment for Australian melanoma patients can save taxpayers millions of dollars annually.
    Gedye C; Boyle FM
    Med J Aust; 2015 Feb; 202(3):130. PubMed ID: 25669468
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of potential cost savings through chemotherapy and biotherapy dose-rounding at a pediatric institution.
    Graff JM; Cramer J; Kolb LL; Agherrabi Z; Burgess M
    J Oncol Pharm Pract; 2024 Jun; 30(4):705-709. PubMed ID: 37350075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of ipilimumab for patients with metastatic melanoma.
    Weber JS; O'Day S; Urba W; Powderly J; Nichol G; Yellin M; Snively J; Hersh E
    J Clin Oncol; 2008 Dec; 26(36):5950-6. PubMed ID: 19018089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case series.
    Jones PS; Cahill DP; Brastianos PK; Flaherty KT; Curry WT
    Neurosurg Focus; 2015 Mar; 38(3):E5. PubMed ID: 25727227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.
    Del Vecchio M; Di Guardo L; Ascierto PA; Grimaldi AM; Sileni VC; Pigozzo J; Ferraresi V; Nuzzo C; Rinaldi G; Testori A; Ferrucci PF; Marchetti P; De Galitiis F; Queirolo P; Tornari E; Marconcini R; CalabrĂ² L; Maio M
    Eur J Cancer; 2014 Jan; 50(1):121-7. PubMed ID: 24100024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost of ipilimumab toxicity: a single-centre analysis.
    Yousaf N; Davidson M; Goode E; Thomas C; Hung R; Gore M; Larkin J
    Melanoma Res; 2015 Jun; 25(3):259-64. PubMed ID: 25860328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CASE STUDY ON AN IPILIMUMAB COST-CONTAINMENT STRATEGY IN AN ITALIAN HOSPITAL.
    Russi A; Chiarion-Sileni V; Damuzzo V; Di Sarra F; Pigozzo J; Palozzo AC
    Int J Technol Assess Health Care; 2017 Jan; 33(2):199-205. PubMed ID: 28703084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreasing drug waste, reducing drug costs, and improving workflow efficiency through the implementation of automated chemotherapy dose rounding rules in the electronic health record system.
    Shah V; Spence A; Bartels T; Betcher J; Soefje S
    Am J Health Syst Pharm; 2022 Apr; 79(8):676-682. PubMed ID: 34940791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.